• Customer Care
  • (888) 123-4567


At Rise Therapeutics, we develop targeted immunological-based biologics using a unique and proprietary oral delivery platform. We design and produce unique, first-in-class immune modulatory drugs for the treatment of inflammation, autoimmunity, infection, and cancer.

Rise Therapeutics Announces New Funding to Support Clinical Development of its Oral Anti-Inflammatory Drug for Inflammatory Bowel Disease

Rockville, MD. Rise Therapeutics announced today that it has received funding from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institute of Health’s (NIH) to support proof-of-concept clinical testing of their lead therapeutic candidate, R-3750. R-3750 is synthetic biology-based immune cellular medicine being developed for the treatment of Inflammatory Bowel Disease (IBD). 

IBD affects more than 3 million adults in the US each year. IBD is an umbrella term used to encompass two chronic inflammatory diseases of the gastrointestinal tract: Crohn’s disease (CD) and ulcerative colitis (UC). Typically diagnosed in mid to late adulthood, IBD is a lifelong disease that currently has few treatments available, and of those treatments, many have debilitating side effects and risks. However, Rise Therapeutics’ R-3750 therapy represents a novel immune regulatory approach for mediating anti-inflammatory effects in the gut and a promising solution for mitigating colitis. 

"The development of our R-3750 oral immunological-based therapeutic to promote anti-inflammatory processes in the gut represents a promising innovative approach to treating Inflammatory Bowel Disease,” stated Dr. Gary Fanger, President and CEO of Rise Therapeutics. “With our clinical GMP manufacturing infrastructure now online, we enthusiastically look forward to initiating our first-in-human clinical trial to evaluate the activity of R-3750 for treating patients suffering from this lifelong disease. We appreciate the support by the NIH and, in particular, the NIDDK team for helping enable us to develop R-3750 as an innovative new drug candidate.” 

Rise Therapeutics has utilized its proprietary synthetic biology approaches to design a highly innovative cellular medicine called R-3750, to treat IBD. As an immunologically-directed microbiome medication, R-3750 is orally administered as a capsule, representing a novel breakthrough approach for the treatment of IBD. 

Rise Therapeutics is an experienced oral therapeutics developer focused on launching promising products to the patients who need them the most. Rise Therapeutics has a robust oral therapeutics pipeline and is proud to partner with The University of Florida and the NIH on this exciting program. 

About Rise Therapeutics  

Rise Therapeutics is an emerging, privately held company located in Rockville, Maryland which leverages its expertise in synthetic biology and immunological drug development to create novel cellular-based immune therapies. With a strong emphasis on product development and its internal clinical GMP manufacturing infrastructure, Rise is focused on developing immunological-based biological medicines using a unique and proprietary oral biologics delivery platform. Unlike traditional biological therapies which require injection or infusion, Rise Therapeutics’ delivery platform allows simple, convenient, and cost-effective oral capsule delivery of targeted protein therapy. The drug development focus at Rise Therapeutics is driven by new microbiome-related discoveries enabling development of rapidly advancing life changing cellular-based medicines to the market for the treatment of inflammation, autoimmunity, cancer, and infection. For more information, go to www.risetherapeutics.com.